FDA
-
-
-
-
-
-
-
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
-
-
-
-
-
-
-
Profound Medical 2023 Virtual Analyst & Investor Day Agenda
-
-
-
-
-
-
-
Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
-
-
-
-
-
-
-
Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer
-
-
-
-
-
-
-
Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference
-
-
-
-
-
-
-
Profound Medical to Release First Quarter 2022 Financial Results on May 9 – Conference Call to Follow
-
-
-
-
-
-
-
Kenneth Knudson Joins Profound Medical as Chief Commercial Officer
-
329,989 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

